Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Adam Turpcu, PhD
Principal Health Economist
Genentech, Inc
South San Francisco, CA
Principal Health Economist, Genentech, Inc, South San Francisco, CA
Authored Items
Longitudinal Commercial Claims–Based Cost Analysis of Diabetic Retinopathy Screening Patterns
Kathryn Fitch, RN, MEd
,
Thomas Weisman, MD,MBA
,
Sharon Glave Frazee, PhD, MPH
,
Tyler Engel, ASA, MAAA
,
Adam Turpcu, PhD
,
Helen Blumen, MD, MBA
,
Yamina Rajput, MS
,
Purav Dave, MS, MBA
September 2015 Vol 8, No 6
in
Original Research
Last modified: September 29, 2015